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A B S T R A C T
b-D-Salicin 1 (Mahdi et al. [8]) is an interesting medicinal phytochemical that exhibits cross functions in
plants and humans immunologically. This molecule 1 (Mahdi et al. [8]) has attracted the attention of
scientists in various interdisciplinary ﬁelds, including chemistry, pharmacology and medicine. The
biological cross functions of b-D-salicin 1 (Mahdi et al. [8]) serve in plant survival and healing processes
via salicylic acid 2 (Pierpont [23]). Thus, this raise a question whether plant biosynthesis and human
metabolism crosstalk to induce therapy via molecular recognition. If so, biotechnology and
bioinformatics are signiﬁcant techniques for new strategies in drug development. Thus, understanding
the biosynthesis, metabolism and the cross-molecular setting of recognition may encourage further
discussion and research on its medicinal and biological activity virtues.
ã 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
The willow tree, like any other medicinal plant species, can be
considered as a bioreactor for the biosynthesis of many
phytochemicals, including b-D-salicin 1. These phytochemicals
are recognised as secondary metabolites, which contribute to the
biology of plants, as they are essential for growth, reproduction
and have important roles in the ecological survival of plants
against biotic and abiotic stress [1–7]. The accumulation of
knowledge on phytochemistry, pharmacology and pharmacognosy
and the rapid development of analytical techniques in chemistry
all have profoundly contributed to the discovery of b-D-salicin 1
and its metabolite, salicylic acid 2. The elucidation of the chemical
structures of these two phytochemicals, 1 and 2, leads the
discovery of the most common anti-inﬂammatory drug,
acetylsalicylic acid 3 or aspirin [8]. In this respect, researches
have recognised the essential steps for exploiting plants in drug
discovery and development. These steps include the identiﬁcation
of natural products, characterisation of the chemical structures of
the bioactive molecules, investigating their pharmacological
potentials and identifying the target active sites. The ethnomedical
usage of plants and the retrospective pharmacological activities
have also contributed to the identiﬁcation of biologically active
phytochemicals [9–10]. Per se, b-D-salicin 1 and salicylic acid 2
from willow have been identiﬁed to exert vital pharmacological
roles in modulating the inﬂammatory process and inhibition
of the activation of NF-kB, and subsequent down regulating
COX-2 expression [11–12]. In addition, our recent results using
Schrödinger software showed that b-D-salicin 1 has better binding
afﬁnity with COX-2 (docking score =9.966) and NK-kB (docking
score =9.274) compared to acetylsalicylic acid 3 (docking score
for COX-2 =5.412; for NK-kB=5.525) [13]. Furthermore,
salicylates exhibit other biological activities, including anticancer
and anti-proliferation [12]. The signiﬁcance of b-D-salicin 1
molecule may encourage further understanding into its
cross-biological function. Therefore, the aim of this article is to
explore the mechanistic biosynthetic pathways of b-D-salicin 1,
its metabolism and discuss the genetic cross-talk between pants
and humans.
2. Phytochemistry of b-D-Salicin 1
b-D-Salicin 1 or 2-(hydroxymethyl) phenyl-O-b-D-glucopyra-
noside is the ﬁrst phenolic glycoside discovered in nature with
a molecular mass of 286.27782 g/mol. Its IUPAC name is
(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[2-(hydroxymethyl) phe-
noxy]oxane-3,4,5-triol. b-D-Glucose 4 moiety of b-D-salicin 1
contributes to all ﬁve chiral carbon centres. The chemical structure
of b-D-salicin 1 encompasses b-D-glucose 4 and 2-hydroxybenzyl
alcohol, or salicyl alcohol 5. b-D-Salicin 1 contains seven
oxygen atoms, as H-bond acceptor and ﬁve hydroxyl groups, as
H-bond donors. It 1 also possesses nine rotational bonds that
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control its conformational structure. In addition, the b-D-glucose
4 and salicyl alcohol 5 moieties are bonded by b-1,10-D-glycosidic
bond. These chemical features contribute to the polarity of
b-D-salicin 1. Therefore, the extraction of b-D-salicin 1 requires
a polar solvent system, such as boiling water and ethyl
alcohol. In addition, the presence of D-glucose 4 moiety
contributes to the enhancement of physcochemical properties
of b-D-salicin 1.
3. Biosynthesis of b-D-Salicin 1
Although there have been long-standing biotic and abiotic
interests in b-D-salicin 1, no deﬁned biosynthetic pathway, genes
or enzymes have been illustrated in the literature [14–15].
Nonetheless, adapting the biotechnological approach and utilising
leave tissues and radio labelled precursors have elucidated some
biosynthetic aspects of b-D-salicin 1 in Salix and Populous [16–17].
It reveals that the biosynthesis of b-D-salicin 1 is associated with
phenylpropanoid pathway that starts with L-phenylalanine 6
(Scheme 1). Using radiolabled precursors indicate that the
biosynthesis ofb-D-salicin 1 encompasses ﬁve steps: deamination,
ortho-hydroxylation, b-oxidation, C2 unite elimination and
glucosylation [7,16].
4. Formation of trans cinnamic acid 7
L-Phenylalanine 6 is available in plants and readily
biotransforms into trans cinnamic acid 7 by phenylalanine
ammonialyase (PAL) [18]. Thereby, plants produce a large number
of organic compounds via this biotransformation [19]. The
catalysis of L-phenylalanine 6 involves deamination of
the amino group of a-amino acid. The mechanism of this
biotransformation involves the formation of an enzyme-substrate
complex, generating a carbonium ion intermediate which subse-
quently induces the elimination of the 3-pro-S proton giving
trans-cinnamic acid 7 in a stereospeciﬁc manner (Scheme 2).
5. C2 unite elimination
Salix and Populous utilise trans-cinnamic acid 7 and
trans-coumaric acid 8 in the synthesis of essentially benzoyl-SCoA
9 and salicyloyl-SCoA 10, respectively (Scheme 2). The incorpo-
ration of radiolabelled 7 or 8 in Salix or Populous leave tissues can
readily be transformed stereospeciﬁcally to 3-hydroxy-3-phenyl-
propanoic acid 11 or 3-hydroxy-3-(2-hydroxyphenyl)-propanoic
acid 12 via CoA-dependent b-oxidation [7,20]. Subsequently,
3-hydroxy propanoate side chain of compounds, 13 or 14,
undergo C2 unit elimination to yield 9 or 10 via retro Claisen
condensation (Scheme 2). The mechanism of biotransformation,
in the last two steps, is analogous to the metabolism of fatty
acids in humans [16,20–21]. The elimination of the C2 unit
involves the formation of b-oxophenyl propionyl-CoA 13
or b-oxo-orthohydroxyphenyl propionyl-CoA 14 which is
followed by the nucleophilic attack by thiolase at b-carbonyl
group, forming an enzyme-substrate complex 15 or 16,
respectively. These two complexes, 15 and 16, subsequently,
undergoes a-b-C–C cleavage, resulting in the formation of the
following intermediates: 17, 18, 19. Protonation of 17 gives
acetyl CoA 20 while the intermediate 18 and 19 undergo
nucleophilic attack by acetyl S-CoA to release the enzyme and
form benzoyl-SCoA 9 and salicyloyl-SCoA 10, respectively
(Scheme 2).
Plants modulate the phenylpropanoide pathways by
interconverting benzoate secondary metabolites in response to
the plant’s physiological requirement. Therefore, the exact
mechanism of b-D-salicin 1 biosynthesis may seem difﬁcult to
justify. Using Salix and Populous leaf tissue indicated that
the downstream of b-D-salicin 1 biosynthesis involves inter
conversion of different simple phenolic molecules, including
benzaldehyde 21, benzoic acid 22 and benzoyl-SCoA 9 compounds
in plants [7,16,22,23]. The biotic transformation of cinnamic acid 7,
for example, can undergo direct ortho hydroxylation to give
2-hydroxycinnamic acid 8 or C2 elimination to give benzaldehyde
21 (Scheme 3). Benzaldehyde 21 can also be hydroxylated at ortho
position to give 2-hydroxybenzaldehyde 23. Feeding the leave
tissue of S. purpurea with radiolabelled benzoic acid 22 or benzyl
alcohol 24 gave benzaldehyde 21 via reduction or oxidation
reaction, respectively [7,16]. Further biotic transformation of
compounds 22 and 24 gave salicyl alcohol 5, the precursor of
b-D-salicin 1 (Scheme 3). In addition, benzoyl-SCoA 9 undergoes a
reduction reaction to give benzyl alcohol 24 or benzoic acid 22
(Scheme 3).
In addition, there are other benzoate secondary metabolites
that have been found in Populous, which contribute to the
biosynthesis of phenolic glycosides. These benzoates are
1-hydroxy-6-oxo-2-cyclohexene-1-carboxylic acid 26, benzyl
6-hydroxy-2-cyclohexen-on-oyl 27 and salicyl 6-hydroxy-2-
cyclohexen-on-oyl 28 [7,22,23]. The ﬁnal step, in the biosynthesis
of 1, involves glucosylation of salicyl alcohol 5 at the phenyl
hydroxyl group.
6. Glucosylation and its stereospeciﬁcity
In S. populous and other plants, salicylaldehyde 23, its
counterpart SCoA active form 9 or salicyl alcohol 5 can undergo



























Scheme 1. An overview of the b-D-salicin 1 biosynthesis.
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direct and indirect routes that involve the formation of b-D-salicin
1. Radiolabelled salicylaldehyde 23 was readily glucosyled to yield
b-D-helacin 30 when fed to S. purpurea which, subsequently
underwent reduction at the carbonyl group to give b-D-salicin 1
[7,16]. In addition, using radiolabelled b-D-helacin 30 undergoes
similar reduction to give b-D-salicin 1 [27]. Research also found
that using radiolabelled salicyl alcohol 5 can be directly
incorporated in the synthesis of 1 (Scheme 4) [16]. However,
literature indicated that salicyl alcohol 5 is not the direct precursor
of b-D-salicin 1 in higher plants. Although salicyl alcohol 5
can undergo glycosylation reaction, it only underwent 46.4%
incorporation into b-D-salicin 1 while 53.6% of it 22 formed
ortho-hydroxybenzylglucoside 31 [16]. Chemically, there are two
types of hydroxyl group that are present in salicyl alcohol 5:
primary and phenolic. In physiological environments, these two
hydroxyl groups are different in their chemical properties. Primary
hydroxyl (pKa =16–19) is amphoteric, while phenolic hydroxyl
tend to be acidic (pKa =8–10). These chemical properties may
play an essential role in the selectivity of which type of hydroxyl
group preferably undergoes glucosylation. Nonetheless, with a
single enzyme, the ratio of glucosylation is controlled by the
stereo-speciﬁcity or by the relative biochemical reactivity of
hydroxyl groups.
The stereochemistry of the b-glycosidic bond formation in
b-D-salicin 1 is based on transglycosylation of glycan (D-glucose)
with an aglycan (benzoate) compound. The mechanism that
controls the conﬁguration of the b-bond requires two carboxylate
residues on the enzyme that are spatially proximal within about
6.0Å [28]. In this mechanism, the two nucleophilic carboxgylates
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Scheme 2. The stereospeciﬁc biosynthetic transformation of L-phenylalanine for generating benzoic acid-related analogues.
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The nucleophilic carboxylate of glucosidase attacks the anomeric
centre of D-glucose 4 to form an enzyme-substrate complex,
while the acid/base residue protonates the glycosidic oxygen
and subsequently activates a compound acceptor to form the
transglycosylated product 1 [28].
7. Metabolism of b-D-Salicin 1
b-D-Salicin 1 is a pro-antiinﬂammatory drug which upon
oral administration, is metabolised into the pharmacological
active form, salicylic acid 2. This metabolic step takes place in
the gastrointestinal tract and blood stream which involves
glycon hydrolysis and oxidation of benzyl carbon. Similarly,
acetylsalicylic acid 3 is also hydrolysed into salicylic acid 2 and
acetic acid.
The route to the metabolism of these drugs has been associated
with esterases that are found in the intestinal mucosa and serum
cytosol [29]. Salicylic acid 2 undergoes further metabolism in the
liver and kidney, as part of drug clearance (Scheme 6). Cytochrome
p-450 enzyme system in mitochondria is capable of catalysing
salicylate into different metabolites, including 2,3,5-trihydroxy
benzoic acid 32, 2,5-dihydroxy benzoic 33 acid and catechol 34;
the decarboxylated analogue of compound 35 [30–32]. The
biotransformation is likely to involve enzymatic hydroxylation
or radical oxidation. In addition, salicylic acid 2 is readily available
for conjugation reactionwith glycine 36 to form salicyluric acid 37
or D-glucuronic acid 38 to form salicylacyl glucuronide 39 or
1-salicylate glucuronide 40 via the formation of ether or ester
bonds (Scheme 6).
The mechanism of aryl hydroxylation involves a cyclohexa-
dienyl radical intermediate followed by hydroxy radical attack
(Scheme 7A). While the biotransformation of 2 compound, in the
presence of glycine 36 or D-glucuronic acid 38, in the liver and
kidney gives, respectively, 37 and 39 and 40 compounds. The
mechanism of these reactions involves nucleophilic addition of
amino group or hydroxyl group to the carbonyl group of salicylic
acid 2, as illustrated in Scheme 7B. In addition, the carboxylic
group (pKa = 4.5) is characterised as a week acid, and it is readily
available to interact with any congruent amino group (pKa = 10.5)
or hydroxyl group (pKa = 10) forming amide or ester bonds,
respectively (Scheme 7B).
The interactions of carboxylic group in salicylic acid 2 with
macromolecules must be tightly associated with the cellular
recognition which mainly depends on the compatibility of the
inter-relationship between compounds to interact with each other.
Salicylic acid 2 possesses three functional groups, as indicated
above, which allow different biochemical interactions to take place
within the cellular molecular biology. The functional groups
also allow appropriate modiﬁcations, with the aim to improve its
anti-inﬂammatory and pro-apoptotic efﬁcacy.
8. Molecular recognition and cross-function of b-D-Salicin 1
The molecular recognition is a fundamental concept of how
molecules communicate with their partners in micro-environ-
ments. The tool for recognition mainly involves molecular
interactions, whereas, functional groups in molecules are the
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Scheme 5. The mechanism of enzymatic glucosylation of slicyl aalcohol 5.
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Scheme 4. Glucosylation of salicyldehyde 23 and salicyl alcohol 5.
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simplest example is water (HOH) whereas both hydrogen and
oxygen atoms contribute to the formation of hydrogen bonding
with other water molecules. In addition, molecules containing
functional groups (e.g. OH, SH, NH) also may interact with
each other. b-D-Salicin 1 and salicylic acid 2 contain mainly
hydroxyl groups (OH) that can interact with cyclooxygenase-2,
causing the inhibition of this enzyme and subsequently down-
regulating inﬂammation [11–12]. Thus, molecular recognition is
often the main dynamic process of any signalling cascade. As such,
the molecular recognition is vital for understanding drug-receptor
interaction, and drug development. In order for the molecule to
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Scheme 6. An overview of the metabolism of b-D-salicin 1 and related compounds.
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the interactedmolecules must mach. Thus, for salicylic acid 2 to be
recognised by the active site of cyclooxygenase-2, both must have
matched geometry that allows the interaction. However, it is not
yet clear how salicylic acid 2 is directly recognised by some
inﬂammatory mediators while b-D-salicin 1 must be metabolised
to exert its anti-inﬂammatory potential. Owing to the random
nature of macromolecules to recognise xenobiotic molecules, they
may generate an expression on howmolecules communicate with
each other to produce speciﬁc function. However, random
interaction may not be suitable in a complex dynamic biological
system. It seems most likely that a genetic match occurs between
speciﬁc phyto-biosynthesis and therapeutic activities to restore
inﬂammatory problems clinically. Per se, humans have identiﬁed
the diversity of herbal medication according to the type of plant.
The earliest explanation to the therapeutic potential of plants goes
back to the Doctorine of Signatures, a philosophy that rationalizes
the similarity in colour or shape between matched parts of plant
and human bodies to coordinate treating an ailment. The other
explanation is related to the co-evolution that is associated with
close proximity between plant and human. In both point of views,
the cross-talkmayexist in engineering DNAs in plant and human in
a way to complement each other.
Although the structure of DNA, in all living things is a
complicated structure, it simply encompasses of only four
repeating nucleotide units; adenine, cytosine, guanine and
thymine, or respectively ACGT. Therefore, plant and human DNAs
are structurally identical in their monomeric composition, but
different in the sequence patterns of these monomers, the
nucleotides. In order to understand the relationship between
biosynthesis and pharmacological properties of speciﬁc
phytomolecule, it is important to consider the pattern of the
encoded enzymes in biosynthetic and pharmacological pathways.
The interaction of phyto-molecule with an enzyme requires
recognition of amino acid consensus motifs of this enzyme. In
addition, the pattern of recognition must have its root in the
encoded gene(s) that control both biosynthesis and pharmacology
pathways. In this respect, the availability of high-throughput
technologies in genome and various databases is considered vital
for bioinformatics approach for the analysis of DNA sequence
bioinformatically. The genetic approach that encompasses
encoded speciﬁc gene and or the corresponding expressed proteins
may help us to understand the complementary functional
relationship of phyto-secondary metabolites. This may encourage
the development of new biotechnological strategies for
therapeutic intervention of certain clinical cases. Mapping of
encoded-related genes and analysis of the nucleotides/amino acids
sequences of cascade networks bioinformatically may also
facilitate a quick understanding into the pattern of the cross-talk
between biosynthesis of a phytomolecule and its pharmacological
potential. High-throughput [33], serial analysis of gene expression
[34] andmassively parallel signature sequencing [35] provide good
opportunities for studying sequences and expressions.
9. Conclusion
b-D-Salicin 1 and salicylic acid 2 are interesting phytochemicals
that exert cross-biological functions in plants and humans. This
cross-functionmay be linked to the homological nature of DNAs in
both plants and humans and can be extended to animals and
insects. In this respect, both cell regulatory proteins and nucleic
acids, for example, possess the same amino acids or nucleotides
repeating units, respectively. The match-up between a phyto-
chemical and the corresponding receptor depend on themolecular
recognitions and the stereo-compatibility of the interacted
molecules. Therefore, mapping and analysing gene and expressed
protein sequences of certain biosynthetic/pharmacologyical
related pathways of certain phytochemical bioinformatically
may contribute to devising new strategies in drug production.
As such, b-D-salicin 1 and salicylic acid 2 may represent good
examples in this respect, as both molecules exert biological
activities in plants and humans to antagonise cell molecular
dysfunction.
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